-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Arcturus Therapeutics to Neutral, Lowers Price Target to $12

Benzinga·10/24/2025 10:44:02
Listen to the news
HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers the price target from $60 to $12.